With a rate of mutation 35 percent higher than random chance, this previously unknown weakness could be a major vector for ...
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized ...
HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback